An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

Combining epcoritamab-bysp with standard chemotherapy significantly improved response for patients with relapsed/refractory DLBCL. The regimen also significantly extended survival. The addition of ...

In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.

including diffuse large B-cell lymphoma not otherwise specified, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma, after two or more lines of systemic therapy who are not ...

However, they raised questions about where the combination of lenalidomide, rituximab and brentuximab vedotin regimen fits into the treatment landscape for relapsed or refractory DLBCL given the ...

Yes, say the authors of a new study, which found that a mere 5% of routine follow-up visits among patients with diffuse large B-cell lymphoma (DLBCL) in remission resulted in detection of relapse.

Approval is based on positive data from the Phase 3 ECHELON-3 trial, which demonstrated ADCETRIS regimen reduced ... lines of therapy with R/R diffuse large B-cell lymphoma (DLBCL) Milestone ...

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated diffuse large B-cell lymphoma ... showed that the regimen achieved a 100% ...

in combination with lenalidomide and a rituximab product for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma ...